Project will kick off with $3 million from The Lilly Foundation to JDRF.

The Juvenile Diabetes Research Foundation (JDRF) and Eli Lilly have established an initiative to accelerate discovery and development of a cure for diabetes through biomarker research.

The effort, called the JDRF-Lilly Innovative and Academic Research and Development Grants in Diabetes Biomarkers, will be stimulated by a $3 million award over three years from the Lilly Foundation to JDRF.

This JDRF-Lilly will support research on biomarkers for pancreatic beta cell mass and function. Both academic and commercial scientists can apply for grants from this initiative. The review process, under the auspices of JDRF, will include both peer scientific review and lay review committees. Those awarded Academic Research and Development grants, will be matched with specific scientific targets.

Previous articleNIH to Put Down $6.8M for Project Focused on Standardizing Measures for Genetic Studies
Next articleSingulex Inks Separate Deals to Enhance the Clinical Utility of Biomarker Assays